Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jun:41:102135.
doi: 10.1016/j.msard.2020.102135. Epub 2020 Apr 18.

Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19

Gavin Giovannoni  1
Affiliations
Comment

Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19

Gavin Giovannoni. Mult Scler Relat Disord. 2020 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest In the last five years, I have received research grant support from Biogen, Merck, Novartis, Roche, Sanofi-Genzyme and Takeda. I have also received personal compensation for participating on Advisory Boards in relation to clinical trial design, trial steering committees and data and safety monitoring committees from Abbvie, Actelion, Atara Bio, Biogen, Canbex Celgene, Genentech, MedDay, Merck, Novartis, Roche, Sanofi-Genzyme and Teva.

Figures

Fig. 1
Fig. 1
UK intensive care data on the proportion of patients admitted to ITU on immunosuppression with either severe COVID-19 or viral pneumonia. These data are derived from the ICNARC Case Mix Programme Database. The Case Mix Programme is the national clinical audit of patient outcomes from adult critical care coordinated by the Intensive Care National Audit & Research Centre (ICNARC). For more information on the representativeness and quality of these data, please contact ICNARC.
See this image and copyright information in PMC

Comment on

References

    1. Alasdair Coles and the MS Advisory Group . Association of British Neurologists; 2020. ABN Guidance on the Use of Disease-Modifying Therapies in Multiple Sclerosis in Response to the Threat of a Coronavirus Epidemic [WWW Document]https://cdn.ymaws.com/www.theabn.org/resource/collection/65C334C7-30FA-4... URL. (accessed 4.13.20)
    1. Hauser S.L., Bar-Or A., Comi G., Giovannoni G., Hartung H.-.P., Hemmer B., Lublin F., Montalban X., Rammohan K.W., Selmaj K., Traboulsee A., Wolinsky J.S., Arnold D.L., Klingelschmitt G., Masterman D., Fontoura P., Belachew S., Chin P., Mairon N., Garren H., Kappos L., OPERA I and OPERA II Clinical Investigators Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 2017;376:221–234. - PubMed
    1. Mayer L., Kappos L., Racke M.K., Rammohan K., Traboulsee A., Hauser S.L., Julian L., Köndgen H., Li C., Napieralski J., Zheng H., Wolinsky J.S. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized opera I, opera II, and oratorio studies. Mult. Scler. Relat. Disord. 2019;30:236–243. - PubMed
    1. Montalban X., Hauser S.L., Kappos L., Arnold D.L., Bar-Or A., Comi G., de Seze J., Giovannoni G., Hartung H.-.P., Hemmer B., Lublin F., Rammohan K.W., Selmaj K., Traboulsee A., Sauter A., Masterman D., Fontoura P., Belachew S., Garren H., Mairon N., Chin P., Wolinsky J.S., ORATORIO Clinical Investigators Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med. 2017;376:209–220. - PubMed
    1. Nicolini L.A., Canepa P., Caligiuri P., Mikulska M., Novi G., Viscoli C., Uccelli A. Fulminant hepatitis associated with echovirus 25 during treatment with ocrelizumab for multiple sclerosis. JAMA Neurol. 2019;76:866–867. - PMC - PubMed